Related Experiment Video

Updated: Aug 26, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.1K

Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease

Husam M Salah1, Marat Fudim2

  • 1Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Heart Failure Clinics
|October 10, 2022
PubMed

Insights

Sodium-glucose cotransporter 2 (SGLT2) inhibitors show promise for treating nonalcoholic fatty liver disease (NAFLD). This review explores evidence and mechanisms, suggesting SGLT2 inhibitors may improve insulin sensitivity and reduce liver fat.

Area of Science:

  • Hepatology
  • Endocrinology
  • Pharmacology

Background:

  • Nonalcoholic fatty liver disease (NAFLD) is a prevalent systemic disorder with significant cardiovascular implications.
  • Current pharmacologic treatments for NAFLD are limited due to its complex pathophysiology.
  • Emerging evidence suggests Sodium-glucose cotransporter 2 (SGLT2) inhibitors may offer therapeutic benefits.

Purpose of the Study:

  • To review preclinical and clinical evidence supporting the use of SGLT2 inhibitors in managing NAFLD.
  • To elucidate the potential mechanisms by which SGLT2 inhibitors exert beneficial effects on NAFLD.

Main Methods:

  • Systematic review of preclinical (animal) studies.
  • Analysis of human clinical trial data.
  • Exploration of proposed molecular and cellular mechanisms.

Main Results:

  • Preclinical and clinical studies indicate SGLT2 inhibitors may reduce NAFLD incidence and progression.
  • Proposed mechanisms include enhanced insulin sensitivity and reduced intrahepatic fat accumulation.
  • Further benefits may involve decreased oxidative stress, endoplasmic reticulum stress, and improved autophagy.

Conclusions:

  • SGLT2 inhibitors represent a potential therapeutic strategy for NAFLD.
  • The multifaceted mechanisms of action warrant further investigation in clinical settings.
  • Targeting SGLT2 may offer a novel approach to managing this complex liver disease.
Keywords:
MechanismsNAFLDNonalcoholic fatty liver diseasePathophysiologySGLT2 inhibitors

More Related Videos

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.0K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.1K

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
238
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
269
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
235
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.0K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
389
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
226